You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 14, 2025

Claims for Patent: 11,752,199

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,752,199

Title:	Methods of modulating pericytes
Abstract:	The present disclosure is directed to methods of modulating pericytes in subjects in need thereof.
Inventor(s):	Dale Wright
Assignee:	Mallinckrodt Ard Ip Unlimited Co, Mallinckrodt Pharmaceuticals Ireland Ltd
Application Number:	US17/185,586
Patent Claims:	1. A method of promoting new vessel formation in a subject in need thereof, the method comprising administering an adrenal corticotropin treatment, wherein VCAM-1 expression and angiopoietin-2 expression is increased after the administering. 2. The method of claim 1, wherein the adrenal corticotropin treatment comprises a repository corticotropin injection (RCI). 3. The method of claim 2, wherein the repository corticotropin injection is a naturally sourced complex mixture of adrenocorticotropic hormone analogs and other pituitary peptides. 4. The method of claim 3, wherein the respository corticotropin injection comprises N-25 deamidated porcine ACTH (1-39). 5. The method of claim 1, wherein the adrenal corticotropin treatment is administered at a daily dose of 30-150 U/m2 over a 2-3 week period. 6. The method of claim 5, wherein the daily dose is gradually tapered over a 2 week period. 7. The method of claim 5, wherein peak VCAM-1 expression and angiopoietin-2 expression is after 3 weeks of administration. 8. A method of promoting new vessel formation in a subject in need thereof, the method comprising administering an adrenal corticotropin treatment to a subject in need thereof, wherein VCAM-1 expression and angiopoietin-2 expression is increased following 3 weeks of administering the adrenal corticotropin. 9. The method of claim 8, further comprising isolating a microvessel from the treated subject. 10. The method of claim 9, further comprising staining the isolated microvessel from the treated subject. 11. The method of claim 10, further comprising counting an increased number of vessels per square mm from the isolated microvessel. 12. The method of claim 8, wherein maximum angiopoietin-2 expression is reached after 3 weeks of administering the adrenal corticotropin.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.